Nektar

‘Tis the Season: Job Cuts and C-Suite Shifts at Novartis, BridgeBio and Nektar
BioSpace
Wed, 04/27/22 - 10:59 am
Novartis
Nektar
BridgeBio
layoffs
restructuring
executives
Nektar Left Reassessing After Canceled Melanoma Trials
BioSpace
Tue, 03/15/22 - 11:38 pm
Nektar
Bristol Myers Squibb
clinical trials
melanoma
bempegaldesleukin
Cytokine interest shows no sign of waning
EP Vantage
Thu, 08/26/21 - 10:45 am
cytokines
Nektar
Bristol Myers Squibb
Proleukin
2 Biotechs Battling Against Kidney Cancer
Motley Fool
Sun, 04/19/20 - 11:06 pm
kidney cancer
Nektar
Exelixis
SITC – the morning after the night before
EP Vantage
Mon, 11/11/19 - 07:51 pm
SITC
NextCure
Pieris
Celyad
Nektar
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Sun, 06/2/19 - 01:12 pm
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
FDA pushes PDUFA for Nektar opioid analgesic
BioCentury
Thu, 02/28/19 - 09:16 pm
Nektar
FDA
NKTR-181
opioids
chronic low back pain
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Yahoo/Reuters
Sat, 02/16/19 - 03:53 pm
Nektar
Bristol-Myers Squibb
bladder cancer
NKTR-214
Opdivo
ASCO18: Who were the big winners and losers?
Biopharma Dive
Wed, 06/6/18 - 04:06 pm
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Sun, 06/3/18 - 10:00 am
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
Thu, 05/17/18 - 10:44 pm
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Wed, 04/11/18 - 09:18 am
Nektar
NKTR-214
NKTR-262
Why Alkermes Sunk Today
Motley Fool
Thu, 02/22/18 - 11:17 pm
Alkermes
ALKS-4230
Nektar
NKTR-214
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
Fri, 12/22/17 - 09:46 am
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
Yahoo/Zacks.com
Sat, 11/25/17 - 12:29 pm
Nektar
AstraZeneca
Movantik
Onzeald
UCB Pharma
Cimzia
Amgen
Neulasta
3 Biotech Stocks to Be Thankful for This Year
Yahoo/Motley Fool
Mon, 11/20/17 - 09:30 am
biotech
Loxo Oncology
Nektar
Spectrum Pharmaceuticals
[video]What’s Next for Nektar Therapeutics?
Motley Fool
Sun, 11/19/17 - 09:47 am
Nektar
NKTR-181
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
NASDAQ.com
Mon, 11/13/17 - 10:54 am
Nektar
NKTR-214
Opdivdo
Bristol-Myers Squibb

Pages